{trans-4-[4-(6-carbamoyl-3-methyl-5-phenylpyrazin-2-yl)phenyl]cyclohexyl}acetic acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: {trans-4-[4-(6-carbamoyl-3-methyl-5-phenylpyrazin-2-yl)phenyl]cyclohexyl}acetic acid
• 英文别名: 2-[4-[4-(6-Carbamoyl-3-methyl-5-phenylpyrazin-2-yl)phenyl]cyclohexyl]acetic acid；2-[4-[4-(6-carbamoyl-3-methyl-5-phenylpyrazin-2-yl)phenyl]cyclohexyl]acetic acid
• 化学式: C₂₆H₂₇N₃O₃
• 分子量: 429.519
• InChiKey: KVKWRYLHEXHJBM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  32
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  106
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  (1Z)-2-偶氮基-1-乙氧基-3-氧代-3-苯基-1-丙烯-1-醇 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 potassium dihydrogenphosphate 、 辛酸铑 、 benzotriazol-1-yloxyl-tris-(pyrrolidino)-phosphonium hexafluorophosphate 、 氯化铵 、 N,N-二异丙基乙胺 、 三氟乙酸 、 lithium hydroxide 、 三氯氧磷 作用下， 以 四氢呋喃 、 乙二醇二甲醚 、 乙醇 、 二氯甲烷 、 水 、 1,2-二氯乙烷 、 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 反应 15.33h， 生成 {trans-4-[4-(6-carbamoyl-3-methyl-5-phenylpyrazin-2-yl)phenyl]cyclohexyl}acetic acid
  参考文献：
  名称：

  Design and Optimization of Pyrazinecarboxamide-Based Inhibitors of Diacylglycerol Acyltransferase 1 (DGAT1) Leading to a Clinical Candidate Dimethylpyrazinecarboxamide Phenylcyclohexylacetic Acid (AZD7687)

  摘要：

  A new series of pyrazinecarboxamide DGAT1 inhibitors was designed to address the need for a candidate drug with good potency, selectivity, and physical and DMPK properties combined with a low predicted dose in man. Rational design and optimization of this series led to the discovery of compound 30 (AZD7687), which met the project objectives for potency, selectivity, in particular over ACAT1, solubility, and preclinical PK profiles. This compound showed the anticipated excellent pharmacokinetic properties in human volunteers.

  DOI：

  10.1021/jm301296t

文献信息

• Design and Optimization of Pyrazinecarboxamide-Based Inhibitors of Diacylglycerol Acyltransferase 1 (DGAT1) Leading to a Clinical Candidate Dimethylpyrazinecarboxamide Phenylcyclohexylacetic Acid (AZD7687)
  作者：Jonas G. Barlind、Udo A. Bauer、Alan M. Birch、Susan Birtles、Linda K. Buckett、Roger J. Butlin、Robert D. M. Davies、Jan W. Eriksson、Clare D. Hammond、Ragnar Hovland、Petra Johannesson、Magnus J. Johansson、Paul D. Kemmitt、Bo T. Lindmark、Pablo Morentin Gutierrez、Tobias A. Noeske、Andreas Nordin、Charles J. O’Donnell、Annika U. Petersson、Alma Redzic、Andrew V. Turnbull、Johanna Vinblad

  DOI：10.1021/jm301296t

  日期：2012.12.13

  A new series of pyrazinecarboxamide DGAT1 inhibitors was designed to address the need for a candidate drug with good potency, selectivity, and physical and DMPK properties combined with a low predicted dose in man. Rational design and optimization of this series led to the discovery of compound 30 (AZD7687), which met the project objectives for potency, selectivity, in particular over ACAT1, solubility, and preclinical PK profiles. This compound showed the anticipated excellent pharmacokinetic properties in human volunteers.